In primary breast cancers and pre-invasive lesions, aberrant KEAP1 promoter methylation was seen to be associated to the estrogen receptor (ER)-positive status and was hypothesized to be a prognostic marker of mortality risk [19]. This evidence concerns the gene ESR1 and breast carcinoma.